Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Open-label Study Comparing 2 Different Strategies For Management Of Subjects With Plaque Psoriasis Who Have Responded To Etanercept Treatment

Next Previous
Search
Trial Profile

Randomized Open-label Study Comparing 2 Different Strategies For Management Of Subjects With Plaque Psoriasis Who Have Responded To Etanercept Treatment

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Etanercept (Primary)
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Acronyms ReSPONSE
  • Sponsors Pfizer

    • Most Recent Events

    • 14 May 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 12 Mar 2013 Planned End Date changed from 1 May 2013 to 1 Apr 2013 as reported by ClinicalTrials.gov.
    • 21 Jul 2012 Additional location (Portugal) added as reported by European Clinical Trials Database.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top